rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Nathalie Dubois-Stringfellow

SVP-Chief Development Officer

Company insider

Files Form 4 as: SVP-Chief Development Officer, Sangamo Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
38
Buys
0
Sells
1
Bought
$0
Sold
$179K
Companies
1
Companies where not an officer
0
First trade
24 Feb 2023
Last trade
25 May 2026
Last filed
27 May 2026

Companies traded

Where they are an officer
Sangamo TherapeuticsOfficer · Biotechnology · last 25 May 20260 buys · 1 sell

Activity over time

1 Apr – 1 Oct
10Apr 26Jun 26Jul 26Sep 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
25 May 2026filed 27 May 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Code F$7034,036 at $0.1743filing
25 May 2026filed 27 May 2026Sangamo TherapeuticsSEC FORM 4 Code F$6864,036 at $0.17filing
21 Apr 2026filed 23 Apr 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Sold$89K345,942 at $0.2578filing
21 Apr 2026filed 23 Apr 2026Sangamo TherapeuticsSEC FORM 4 Sold$90K345,942 at $0.26filing
1 Apr 2026filed 3 Apr 2026Sangamo Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—800,000 at $0.00filing
1 Apr 2026filed 3 Apr 2026Sangamo Therapeuticsoption or derivativeSEC FORM 4 Code A—800,000 at $0.00filing
25 Feb 2026filed 26 Feb 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Code F$5,80612,354 at $0.47filing
25 Feb 2026filed 26 Feb 2026Sangamo TherapeuticsSEC FORM 4 Code F$5,80612,354 at $0.47filing
24 Feb 2026filed 26 Feb 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Code F$9752,063 at $0.4725filing
24 Feb 2026filed 26 Feb 2026Sangamo TherapeuticsSEC FORM 4 Code F$9702,063 at $0.47filing
22 Jan 2026filed 26 Jan 2026Sangamo TherapeuticsBiotechnologySEC FORM 4 Code F$15K36,676 at $0.3985filing
22 Jan 2026filed 26 Jan 2026Sangamo TherapeuticsSEC FORM 4 Code F$15K36,676 at $0.40filing
24 Nov 2025filed 26 Nov 2025Sangamo TherapeuticsSEC FORM 4 Code F$1,0682,544 at $0.42filing
22 Oct 2025filed 24 Oct 2025Sangamo TherapeuticsSEC FORM 4 Code F$29K43,741 at $0.66filing
24 Aug 2025filed 26 Aug 2025Sangamo TherapeuticsSEC FORM 4 Code F$1,0571,792 at $0.59filing
22 Jul 2025filed 24 Jul 2025Sangamo TherapeuticsSEC FORM 4 Code F$15K31,866 at $0.48filing
24 May 2025filed 28 May 2025Sangamo TherapeuticsSEC FORM 4 Code F$8421,792 at $0.47filing
22 Apr 2025filed 24 Apr 2025Sangamo TherapeuticsSEC FORM 4 Code F$25K31,866 at $0.78filing
25 Feb 2025filed 26 Feb 2025Sangamo Therapeuticsoption or derivativeSEC FORM 4 Code A—560,000 at $0.00filing
25 Feb 2025filed 26 Feb 2025Sangamo TherapeuticsSEC FORM 4 Code F$1,4521,513 at $0.96filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care1
Not placed1

Buys in green, sells in red, by the company’s sector.

Related people

Sandy MacraePresident, CEO and Director · President, CEO and Director at Sangamo Therapeutics, filing Form 4 there in the last year
Scott B. WilloughbySVP, Chief Legal Officer, Secy · SVP, Chief Legal Officer, Secy at Sangamo Therapeutics, filing Form 4 there in the last year
Gregory D. DavisHead of Research & Technology · Head of Research & Technology at Sangamo Therapeutics, filing Form 4 there in the last year
Nikunj JainPrincipal Accounting Officer · Principal Accounting Officer at Sangamo Therapeutics, filing Form 4 there in the last year
Prathyusha DuraibabuDirector · Principal Financial Officer at Sangamo Therapeutics, filing Form 4 there in the last year